131 related articles for article (PubMed ID: 34381816)
1. The Tumorigenic Properties of EZH2 are Mediated by MiR-26a in Uveal Melanoma.
Li Y; Zhang M; Feng H; Mahati S
Front Mol Biosci; 2021; 8():713542. PubMed ID: 34381816
[No Abstract] [Full Text] [Related]
2. MiRNA-26a Contributes to the Acquisition of Malignant Behaviors of Doctaxel-Resistant Lung Adenocarcinoma Cells through Targeting EZH2.
Chen J; Xu Y; Tao L; Pan Y; Zhang K; Wang R; Chen LB; Chu X
Cell Physiol Biochem; 2017; 41(2):583-597. PubMed ID: 28214878
[TBL] [Abstract][Full Text] [Related]
3. A double-negative feedback loop between EZH2 and miR-26a regulates tumor cell growth in hepatocellular carcinoma.
Zhuang C; Wang P; Huang D; Xu L; Wang X; Wang L; Hu L
Int J Oncol; 2016 Mar; 48(3):1195-204. PubMed ID: 26781064
[TBL] [Abstract][Full Text] [Related]
4. MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2.
Lu J; He ML; Wang L; Chen Y; Liu X; Dong Q; Chen YC; Peng Y; Yao KT; Kung HF; Li XP
Cancer Res; 2011 Jan; 71(1):225-33. PubMed ID: 21199804
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-26a suppresses epithelial-mesenchymal transition in human hepatocellular carcinoma by repressing enhancer of zeste homolog 2.
Ma DN; Chai ZT; Zhu XD; Zhang N; Zhan DH; Ye BG; Wang CH; Qin CD; Zhao YM; Zhu WP; Cao MQ; Gao DM; Sun HC; Tang ZY
J Hematol Oncol; 2016 Jan; 9():1. PubMed ID: 26733151
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-137 targets EZH2 to exert suppressive functions in uveal melanoma via regulation of Wnt/β-catenin signaling and epithelial-to-mesenchymal transition.
Zhang J; Liu G; Jin H; Li X; Li N; Yin Q; Hu R
J BUON; 2021; 26(1):173-181. PubMed ID: 33721449
[TBL] [Abstract][Full Text] [Related]
7. LncRNA SNHG6 promotes the migration, invasion, and epithelial-mesenchymal transition of colorectal cancer cells by miR-26a/EZH2 axis.
Zhang M; Duan W; Sun W
Onco Targets Ther; 2019; 12():3349-3360. PubMed ID: 31118686
[No Abstract] [Full Text] [Related]
8. MicroRNA-26a regulates tumorigenic properties of EZH2 in human lung carcinoma cells.
Dang X; Ma A; Yang L; Hu H; Zhu B; Shang D; Chen T; Luo Y
Cancer Genet; 2012 Mar; 205(3):113-23. PubMed ID: 22469510
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-26a targets the histone methyltransferase Enhancer of Zeste homolog 2 during myogenesis.
Wong CF; Tellam RL
J Biol Chem; 2008 Apr; 283(15):9836-43. PubMed ID: 18281287
[TBL] [Abstract][Full Text] [Related]
10. miR-26a promoted by interferon-alpha inhibits hepatocellular carcinoma proliferation and migration by blocking EZH2.
Wang G; Sun Y; He Y; Ji C; Hu B; Sun Y
Genet Test Mol Biomarkers; 2015 Jan; 19(1):30-6. PubMed ID: 25494962
[TBL] [Abstract][Full Text] [Related]
11. The protective effects of microRNA-26a in steroid-induced osteonecrosis of the femoral head by repressing EZH2.
Li G; Liu H; Zhang X; Liu X; Zhang G; Liu Q
Cell Cycle; 2020 Mar; 19(5):551-566. PubMed ID: 32054404
[TBL] [Abstract][Full Text] [Related]
12. MiR-26a and miR-138 block the G1/S transition by targeting the cell cycle regulating network in prostate cancer cells.
Erdmann K; Kaulke K; Rieger C; Salomo K; Wirth MP; Fuessel S
J Cancer Res Clin Oncol; 2016 Nov; 142(11):2249-61. PubMed ID: 27562865
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity.
Xu L; Beckebaum S; Iacob S; Wu G; Kaiser GM; Radtke A; Liu C; Kabar I; Schmidt HH; Zhang X; Lu M; Cicinnati VR
J Hepatol; 2014 Mar; 60(3):590-8. PubMed ID: 24211739
[TBL] [Abstract][Full Text] [Related]
14. Verification of EZH2 as a druggable target in metastatic uveal melanoma.
Jin B; Zhang P; Zou H; Ye H; Wang Y; Zhang J; Yang H; Pan J
Mol Cancer; 2020 Mar; 19(1):52. PubMed ID: 32127003
[TBL] [Abstract][Full Text] [Related]
15. Mutant p53 induces EZH2 expression and promotes epithelial-mesenchymal transition by disrupting p68-Drosha complex assembly and attenuating miR-26a processing.
Jiang FZ; He YY; Wang HH; Zhang HL; Zhang J; Yan XF; Wang XJ; Che Q; Ke JQ; Chen Z; Tong H; Zhang YL; Wang FY; Li YR; Wan XP
Oncotarget; 2015 Dec; 6(42):44660-74. PubMed ID: 26587974
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of microRNA-26a is associated with metastatic potential and the poor prognosis of osteosarcoma patients.
Song QC; Shi ZB; Zhang YT; Ji L; Wang KZ; Duan DP; Dang XQ
Oncol Rep; 2014 Mar; 31(3):1263-70. PubMed ID: 24452597
[TBL] [Abstract][Full Text] [Related]
17. High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer.
Jansen MP; Reijm EA; Sieuwerts AM; Ruigrok-Ritstier K; Look MP; Rodríguez-González FG; Heine AA; Martens JW; Sleijfer S; Foekens JA; Berns EM
Breast Cancer Res Treat; 2012 Jun; 133(3):937-47. PubMed ID: 22094936
[TBL] [Abstract][Full Text] [Related]
18. miR-26a inhibits invasion and metastasis of nasopharyngeal cancer by targeting EZH2.
Yu L; Lu J; Zhang B; Liu X; Wang L; Li SY; Peng XH; Xu X; Tian WD; Li XP
Oncol Lett; 2013 Apr; 5(4):1223-1228. PubMed ID: 23599767
[TBL] [Abstract][Full Text] [Related]
19. MiR-26a inhibits cell proliferation and induces apoptosis in human bladder cancer through regulating EZH2 bioactivity.
Zhou B; Wei E; Shi H; Huang J; Gao L; Zhang T; Wei Y; Ge B
Int J Clin Exp Pathol; 2017; 10(11):11234-11241. PubMed ID: 31966476
[TBL] [Abstract][Full Text] [Related]
20. Pathologically decreased miR-26a antagonizes apoptosis and facilitates carcinogenesis by targeting MTDH and EZH2 in breast cancer.
Zhang B; Liu XX; He JR; Zhou CX; Guo M; He M; Li MF; Chen GQ; Zhao Q
Carcinogenesis; 2011 Jan; 32(1):2-9. PubMed ID: 20952513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
